Isamoltane (developmental code name CGP-361A) is a beta blocker (ò-adrenergic receptor antagonist) with additional serotonin 5-HT<sub>1A</sub> and 5-HT<sub>1B</sub> receptor antagonist activity. It has about 5-fold higher affinity for the serotonin 5-HT<sub>1B</sub> receptor (K<sub>i</sub> = 21nM) over the serotonin 5-HT<sub>1A</sub> receptor (K<sub>i</sub> = 112nM). It has anxiolytic effects in rodents. The drug was under development by Novartis and AstraZeneca for the treatment of anxiety disorders in the 1990s but was never marketed.